OverviewCancers originating in the esophagus, gastroesophageal junctions, and stomach constitute a major health problem worldwide. In the United States, 37,600 new diagnoses of and 25,150 deaths from upper gastrointestinal cancers were estimated in 2009.1 A dramatic shift in the location of upper gastrointestinal tumors has occurred in the United States,2 and changes in histology and location of them were observed in some parts of Europe.3,4 In countries in the Western Hemisphere, the most common sites of gastric cancer are the proximal lesser curvature, cardia, and gastroesophageal junction.2 These changing trends may also begin to occur in South America and Asia.EpidemiologyGastric cancer is rampant in many countries around the world. In Japan, it remains the most common type of cancer among men; in China, more new cases are diagnosed each year than in any other country. The incidence of gastric cancer, however, has been declining globally since World War II and it is one of the least common cancers in North America. By some estimates, it is the fourth most common cancer worldwide.5 In 2009, 21,130 new diagnoses of gastric cancer were estimated in the United States and 10,620 deaths expected.1 In developed countries, the incidence of gastric cancer originating from the cardia follows the distribution of esophageal cancer.6–8 Noncardia gastric adenocarcinoma has marked geographic variation, with countries such as Japan, Korea, China, Taiwan, Costa Rica, Peru, Brazil, Chile, and the former Soviet Union showing a high incidence.9 In contrast to the incidence trends in the West, nonproximal...
  • 1.

    JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225249.

  • 2.

    BlotWJDevesaSSKnellerRWFraumeniJF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA1991;265:12871289.

  • 3.

    JohnstonBJReedPI. Changing pattern of oesophageal cancer in a general hospital in the UK. Eur J Cancer Prev1991;1:2325.

  • 4.

    PowellJMcConkeyCC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer1990;62:440443.

  • 5.

    KamangarFDoresGMAndersonWF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol2006;24:21372150.

    • Search Google Scholar
    • Export Citation
  • 6.

    CrewKDNeugutAI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol2004;31:450464.

  • 7.

    KuboACorleyDA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer2002;95:20962102.

    • Search Google Scholar
    • Export Citation
  • 8.

    PowellJMcConkeyCCGillisonEWSpychalRT. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer2002;102:422427.

  • 9.

    CorleyDABufflerPA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol2001;30:14151425.

    • Search Google Scholar
    • Export Citation
  • 10.

    ParkinDMMuirCS. Cancer Incidence in five continents. Comparability and quality of data. IARC Sci Publ1992:45173.

  • 11.

    FitzgeraldRCCaldasC. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut2004;53:775778.

  • 12.

    HuntsmanDGCarneiroFLewisFR. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med2001;344:19041909.

    • Search Google Scholar
    • Export Citation
  • 13.

    Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study in Surgery and Pathology 12th ed.Tokyo: Kanahara Shuppan; 1993.

    • Search Google Scholar
    • Export Citation
  • 14.

    RoderJDBottcherKBuschR. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer1998;82:621631.

    • Search Google Scholar
    • Export Citation
  • 15.

    ChauINormanARCunninghamD. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol2004;22:23952403.

    • Search Google Scholar
    • Export Citation
  • 16.

    KarpehMSLeonLKlimstraDBrennanMF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg2000;232:362371.

    • Search Google Scholar
    • Export Citation
  • 17.

    AbdallaEKPistersPW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol2004;31:513529.

  • 18.

    KweeRMKweeTC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol2007;25:21072116.

  • 19.

    WeberWAOttK. Imaging of esophageal and gastric cancer. Semin Oncol2004;31:530541.

  • 20.

    StahlAOttKWeberWA. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging2003;30:288295.

    • Search Google Scholar
    • Export Citation
  • 21.

    ChenJCheongJHYunMJ. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer2005;103:23832390.

    • Search Google Scholar
    • Export Citation
  • 22.

    RosenbaumSJStergarHAntochG. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging2006;31:2535.

  • 23.

    DassenAELipsDJHoekstraCJ. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol2009;35:449455.

  • 24.

    LimJSYunMJKimMJ. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics2006;26:143156.

    • Search Google Scholar
    • Export Citation
  • 25.

    MatsumotoYYanaiHTokiyamaH. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol2000;35:326331.

    • Search Google Scholar
    • Export Citation
  • 26.

    TsendsurenTJunSMMianXH. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol2006;12:4347.

    • Search Google Scholar
    • Export Citation
  • 27.

    SarelaAILefkowitzRBrennanMFKarpehMS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg2006;191:134138.

    • Search Google Scholar
    • Export Citation
  • 28.

    BentremDWiltonAMazumdarM. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol2005;12:347353.

    • Search Google Scholar
    • Export Citation
  • 29.

    BurkeECKarpehMSJrConlonKCBrennanMF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol1998;5:411415.

    • Search Google Scholar
    • Export Citation
  • 30.

    AjaniJAMayerRJOtaDM. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst1993;85:18391844.

    • Search Google Scholar
    • Export Citation
  • 31.

    LeichmanLSilbermanHLeichmanCG. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol1992;10:19331942.

    • Search Google Scholar
    • Export Citation
  • 32.

    HermanekPWittekindC. Residual tumor (R) classification and prognosis. Semin Surg Oncol1994;10:1220.

  • 33.

    BozzettiFMarubiniEBonfantiG. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg1999;230:170178.

    • Search Google Scholar
    • Export Citation
  • 34.

    ItoHClancyTEOsteenRT. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach?J Am Coll Surg2004;199:880886.

  • 35.

    YuWChoiGSChungHY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg2006;93:559563.

    • Search Google Scholar
    • Export Citation
  • 36.

    KajitaniT. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg1981;11:127139.

    • Search Google Scholar
    • Export Citation
  • 37.

    SchwarzRESmithDD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol2007;14:317328.

    • Search Google Scholar
    • Export Citation
  • 38.

    SanoTSasakoMYamamotoS. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol2004;22:27672773.

    • Search Google Scholar
    • Export Citation
  • 39.

    SasakoMSanoTYamamotoS. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med2008;359:453462.

    • Search Google Scholar
    • Export Citation
  • 40.

    BonenkampJJHermansJSasakoM. Extended lymph-node dissection for gastric cancer. N Engl J Med1999;340:908914.

  • 41.

    CuschieriAWeedenSFieldingJ. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer1999;79:15221530.

    • Search Google Scholar
    • Export Citation
  • 42.

    HartgrinkHHvan de VeldeCJHPutterH. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol2004;22:20692077.

    • Search Google Scholar
    • Export Citation
  • 43.

    McCullochPNitaMEKaziHGama-RodriguesJ. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev2004:CD001964.

    • Search Google Scholar
    • Export Citation
  • 44.

    MansfieldPF. Lymphadenectomy for gastric cancer. J Clin Oncol2004;22:27592761.

  • 45.

    DouglassHOJrHundahlSAMacdonaldJSKhatriVP. Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debate. Surg Oncol Clin N Am2007;16:133155.

    • Search Google Scholar
    • Export Citation
  • 46.

    JansenEPMBootHVerheijMvan de VeldeCJH. Optimal locoregional treatment in gastric cancer. J Clin Oncol2005;23:45094517.

  • 47.

    KhatriVPDouglassHOJr. D2.5 dissection for gastric carcinoma. Arch Surg2004;139:662669; discussion 669.

  • 48.

    van de VeldeCJPeetersKC. The gastric cancer treatment controversy. J Clin Oncol2003;21:22342236.

  • 49.

    DegiuliMSasakoMCalgaroM. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol2004;30:303308.

    • Search Google Scholar
    • Export Citation
  • 50.

    DegiuliMSasakoMPontiACalvoF. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer2004;90:17271732.

    • Search Google Scholar
    • Export Citation
  • 51.

    JatzkoGRLisborgPHDenkH. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer1995;76:13021312.

    • Search Google Scholar
    • Export Citation
  • 52.

    SierraARegueiraFMHernandez-LizoainJL. Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. Ann Surg Oncol2003;10:219226.

    • Search Google Scholar
    • Export Citation
  • 53.

    EnzingerPCBenedettiJKMeyerhardtJA. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg2007;245:426434.

    • Search Google Scholar
    • Export Citation
  • 54.

    HullMJMino-KenudsonMNishiokaNS. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol2006;30:114118.

    • Search Google Scholar
    • Export Citation
  • 55.

    SoetiknoRKaltenbachTYehRGotodaT. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol2005;23:44904498.

    • Search Google Scholar
    • Export Citation
  • 56.

    KoobyDASuriawinataAKlimstraDS. Biologic predictors of survival in node-negative gastric cancer. Ann Surg2003;237:828835.

  • 57.

    BonenkampJJvan de VeldeCJKampschoerGH. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg1993;17:410414.

    • Search Google Scholar
    • Export Citation
  • 58.

    OnoHKondoHGotodaT. Endoscopic mucosal resection for treatment of early gastric cancer. Gut2001;48:225229.

  • 59.

    HyungWJCheongJHKimJ. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol2004;85:181185.

  • 60.

    ReyesCDWeberKJGagnerMDivinoCM. Laparoscopic vs open gastrectomy. A retrospective review. Surg Endosc2001;15:928931.

  • 61.

    HuscherCGMingoliASgarziniG. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg2005;241:232237.

    • Search Google Scholar
    • Export Citation
  • 62.

    SmalleySRGundersonLTepperJ. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys2002;52:283293.

    • Search Google Scholar
    • Export Citation
  • 63.

    ZhangZXGuXZYinWB. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys1998;42:929934.

    • Search Google Scholar
    • Export Citation
  • 64.

    HallisseyMTDunnJAWardLCAllumWH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet1994;343:13091312.

    • Search Google Scholar
    • Export Citation
  • 65.

    ValentiniVCelliniFMinskyBD. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol2009;92:176183.

    • Search Google Scholar
    • Export Citation
  • 66.

    HazardLO' ConnorJScaifeC. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol2006;12:15111520.

  • 67.

    MoertelCGChildsDSReitemeierRJ. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet1969;2:865867.

    • Search Google Scholar
    • Export Citation
  • 68.

    The concept of locally advanced gastric cancer.Effect of treatment on outcome. The Gastrointestinal Tumor Study Group. Cancer1990;66:23242330.

    • Search Google Scholar
    • Export Citation
  • 69.

    MilanoMTGarofaloMCChmuraSJ. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol2006;79:497503.

    • Search Google Scholar
    • Export Citation
  • 70.

    LowyAMFeigBWJanjanN. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol2001;8:519524.

  • 71.

    AjaniJAMansfieldPFCraneCH. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol2005;23:12371244.

    • Search Google Scholar
    • Export Citation
  • 72.

    AjaniJAMansfieldPFJanjanN. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol2004;22:27742780.

    • Search Google Scholar
    • Export Citation
  • 73.

    AjaniJAWinterKOkawaraGS. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol2006;24:39533958.

    • Search Google Scholar
    • Export Citation
  • 74.

    StahlMWalzMKStuschkeM. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol2009;27:851856.

    • Search Google Scholar
    • Export Citation
  • 75.

    BaezaMRGianniniTORiveraSR. Adjuvant radiochemotherapy in the treatment of completely resected, locally advanced gastric cancer. Int J Radiat Oncol Biol Phys2001;50:645650.

    • Search Google Scholar
    • Export Citation
  • 76.

    DentDMWernerIDNovisB. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer1979;44:385391.

  • 77.

    MoertelCGChildsDSO'FallonJR. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol1984;2:12491254.

    • Search Google Scholar
    • Export Citation
  • 78.

    MacdonaldJSSmalleySRBenedettiJ. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725730.

    • Search Google Scholar
    • Export Citation
  • 79.

    MacdonaldJSBenedettiJSmalleyS. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4515.

    • Search Google Scholar
    • Export Citation
  • 80.

    LeeJKangWLimD. Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): safety analysis [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4537.

    • Search Google Scholar
    • Export Citation
  • 81.

    CunninghamDAllumWHStenningSP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:1120.

    • Search Google Scholar
    • Export Citation
  • 82.

    MaeharaY. S-1 in gastric cancer: a comprehensive review. Gastric Cancer2003;6(Suppl 1):28.

  • 83.

    SakuramotoSSasakoMYamaguchiT. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med2007;357:18101820.

    • Search Google Scholar
    • Export Citation
  • 84.

    NakajimaTNashimotoAKitamuraM. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet1999;354:273277.

    • Search Google Scholar
    • Export Citation
  • 85.

    AjaniJA. Evolving chemotherapy for advanced gastric cancer. Oncologist2005;10:4958.

  • 86.

    ShahMASchwartzGK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol2004;31:574587.

  • 87.

    BugatR. Irinotecan in the treatment of gastric cancer. Ann Oncol2003;14(Suppl 2):ii3740.

  • 88.

    EinzigAILipsitzSWiernikPHBensonABIII. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Invest New Drugs1995;13:223227.

    • Search Google Scholar
    • Export Citation
  • 89.

    OhtsuABokuNTamuraF. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol1998;21:416419.

    • Search Google Scholar
    • Export Citation
  • 90.

    AjaniJAFairweatherJDumasP. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am1998;4:269274.

  • 91.

    KimYHShinSWKimBS. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer1999;85:295301.

    • Search Google Scholar
    • Export Citation
  • 92.

    AjaniJA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother2006;7:16271631.

    • Search Google Scholar
    • Export Citation
  • 93.

    SulkesASmythJSessaC. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials group. Br J Cancer1994;70:380383.

    • Search Google Scholar
    • Export Citation
  • 94.

    RothADMaibachRMartinelliG. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol2000;11:301306.

    • Search Google Scholar
    • Export Citation
  • 95.

    AjaniJAMansfieldPFDumasP. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am1999;5:112114.

  • 96.

    Al-BatranSEAtmacaAHegewisch-BeckerS. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol2004;22:658663.

    • Search Google Scholar
    • Export Citation
  • 97.

    LouvetCAndreTTigaudJM. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol2002;20:45434548.

    • Search Google Scholar
    • Export Citation
  • 98.

    TakiuchiHAjaniJA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol1998;16:28772885.

  • 99.

    BoucheORaoulJLBonnetainF. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol2004;22:43194328.

    • Search Google Scholar
    • Export Citation
  • 100.

    BokuNOhtsuAShimadaY. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol1999;17:319323.

    • Search Google Scholar
    • Export Citation
  • 101.

    BrellJMKrishnamurthiSSJavleM. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol2009;63:851857.

    • Search Google Scholar
    • Export Citation
  • 102.

    DankMZaluskiJBaroneC. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2008;19:14501457.

    • Search Google Scholar
    • Export Citation
  • 103.

    EnzingerPCRyanDPClarkJW. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol2009;20:475480.

    • Search Google Scholar
    • Export Citation
  • 104.

    MoehlerMEimermacherASieblerJ. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer2005;92:21222128.

    • Search Google Scholar
    • Export Citation
  • 105.

    MoehlerMKanzlerSGeisslerM. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2010;21:7177.

    • Search Google Scholar
    • Export Citation
  • 106.

    PozzoCBaroneCSzantoJ. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol2004;15:17731781.

    • Search Google Scholar
    • Export Citation
  • 107.

    MoehlerMHaasUSieblerJ. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs2003;14:645650.

    • Search Google Scholar
    • Export Citation
  • 108.

    AjaniJABakerJPistersPWT. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma. Cancer2002;94:641646.

    • Search Google Scholar
    • Export Citation
  • 109.

    GlimeliusBHoffmanKHaglundU. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol1994;5:189190.

    • Search Google Scholar
    • Export Citation
  • 110.

    PyrhonenSKuitunenTNyandotoPKouriM. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer1995;71:587591.

    • Search Google Scholar
    • Export Citation
  • 111.

    MacDonaldJSScheinPSWoolleyPV. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med1980;93:533536.

    • Search Google Scholar
    • Export Citation
  • 112.

    CullinanSAMoertelCGFlemingTR. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA1985;253:20612067.

    • Search Google Scholar
    • Export Citation
  • 113.

    WilsJAKleinHOWagenerDJ. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol1991;9:827831.

    • Search Google Scholar
    • Export Citation
  • 114.

    WebbACunninghamDScarffeJH. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol1997;15:261267.

    • Search Google Scholar
    • Export Citation
  • 115.

    VanhoeferURougierPWilkeH. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol2000;18:26482657.

    • Search Google Scholar
    • Export Citation
  • 116.

    RossPNicolsonMCunninghamD. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:19962004.

    • Search Google Scholar
    • Export Citation
  • 117.

    Al-BatranSEHartmannJTProbstS. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol2008;26:14351442.

    • Search Google Scholar
    • Export Citation
  • 118.

    Van CutsemEMoiseyenkoVMTjulandinS. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:49914997.

    • Search Google Scholar
    • Export Citation
  • 119.

    MoehlerMHThuss-PatiencePArnoldD. Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: interim results from a phase II trial by the German AIO Group [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4554.

    • Search Google Scholar
    • Export Citation
  • 120.

    ShankaranVMulcahyMFHochsterHS. Docetaxel oxaliplatin and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17 2009; San Francisco California>. Abstract 47.

    • Search Google Scholar
    • Export Citation
  • 121.

    AjaniJ. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer2006;107:221231.

  • 122.

    CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:3646.

  • 123.

    KangYKKangWKShinDB. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol2009;20:666673.

    • Search Google Scholar
    • Export Citation
  • 124.

    OkinesAFCNormanARMcCloudP. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol2009;20:15291534.

    • Search Google Scholar
    • Export Citation
  • 125.

    TakahashiIKakejiYEmiY. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer2003;6(Suppl 1):2833.

    • Search Google Scholar
    • Export Citation
  • 126.

    KoizumiWTanabeSSaigenjiK. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer2003;89:22072212.

    • Search Google Scholar
    • Export Citation
  • 127.

    KoizumiWKuriharaMNakanoSHasegawaK. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology2000;58:191197.

    • Search Google Scholar
    • Export Citation
  • 128.

    KoizumiWNaraharaHHaraT. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol2008;9:215221.

    • Search Google Scholar
    • Export Citation
  • 129.

    AjaniJALeeFCSinghDA. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol2006;24:663667.

    • Search Google Scholar
    • Export Citation
  • 130.

    LenzHJLeeFCHallerDG. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer2007;109:3340.

    • Search Google Scholar
    • Export Citation
  • 131.

    AjaniJARodriquezWBodokyG. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4511.

    • Search Google Scholar
    • Export Citation
  • 132.

    GravalosCJimenoA. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008;19:15231529.

  • 133.

    WagnerADMoehlerM. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol2009;21:381385.

    • Search Google Scholar
    • Export Citation
  • 134.

    Van CutsemEKangYChungH. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract LBA4509.

    • Search Google Scholar
    • Export Citation
  • 135.

    EnzingerPCRyanDPReganEM. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4552.

    • Search Google Scholar
    • Export Citation
  • 136.

    KelsenDJhawerMIlsonD. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4512.

    • Search Google Scholar
    • Export Citation
  • 137.

    ShahMARamanathanRKIlsonDH. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol2006;24:52015206.

    • Search Google Scholar
    • Export Citation
  • 138.

    SunWPowellMEO'DwyerP. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4535.

    • Search Google Scholar
    • Export Citation
  • 139.

    PintoCDi FabioFSienaS. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol2007;18:510517.

    • Search Google Scholar
    • Export Citation
  • 140.

    KanzlerSTrarbachTSeufferleinT. Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: a nonrandomized multicenter AIO phase II study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4534.

    • Search Google Scholar
    • Export Citation
  • 141.

    KimCLeeJLRyuMH. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs2010; in press.

    • Search Google Scholar
    • Export Citation
  • 142.

    PintoCDi FabioFBaroneC. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer2009;101:12611268.

    • Search Google Scholar
    • Export Citation
  • 143.

    WoellEGreilREistererW. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4538.

    • Search Google Scholar
    • Export Citation
  • 144.

    ZhangXXuJShenl. A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17 2009; San Francisco California. AbstractLBA39.

    • Search Google Scholar
    • Export Citation
  • 145.

    CheyWDWongBCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol2007;102:18081825.

    • Search Google Scholar
    • Export Citation
  • 146.

    JadvarHTatlidilRGarciaAAContiPS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol2003;58:215221.

    • Search Google Scholar
    • Export Citation
  • 147.

    OttKFinkUBeckerK. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol2003;21:46044610.

    • Search Google Scholar
    • Export Citation
  • 148.

    TianJChenLWeiB. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. Nucl Med Commun2004;25:825831.

    • Search Google Scholar
    • Export Citation
  • 149.

    GlimeliusBEkstromKHoffmanK. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol1997;8:163168.

    • Search Google Scholar
    • Export Citation
  • 150.

    CasarettoLSousaPLRMariJJ. Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res2006;39:431440.

    • Search Google Scholar
    • Export Citation
  • 151.

    Thuss-PatiencePCKretzschmarADeistT. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4540.

    • Search Google Scholar
    • Export Citation
  • 152.

    KarnofskyDABurchenalJH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM ed.Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:199205.

    • Search Google Scholar
    • Export Citation
  • 153.

    OkenMMCreechRHTormeyDC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982;5:649655.

  • 154.

    SchagCCHeinrichRLGanzPA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol1984;2:187193.

  • 155.

    ImbesiJJKurtzRC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol2005;3:101110.

  • 156.

    KimMMRanaVJanjanNA. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol2008;47:421427.

  • 157.

    HoltAPPatelMAhmedMM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice?Gastrointest Endosc2004;60:10101017.

    • Search Google Scholar
    • Export Citation
  • 158.

    LindsayJOAndreyevHJVlavianosPWestabyD. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. Aliment Pharmacol Ther2004;19:901905.

    • Search Google Scholar
    • Export Citation
  • 159.

    KimTOKangDHKimGH. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol2007;13:916920.

    • Search Google Scholar
    • Export Citation
  • 160.

    JeurninkSMvan EijckCHSteyerbergEW. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol2007;7:18.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1224 1224 101
PDF Downloads 182 182 24
EPUB Downloads 0 0 0